After TESARO (TSRO) announced positive trial results for niraparib in ovarian cancer in the maintenance setting, Janney Capital analyst Roy Buchanan said the results "at least further validate" the activities of PARP inhibitors in ovarian cancer. The analyst, who does not cover TESARO, noted that Clovis (CLVS) is on track to complete the NDA for "post-maintenance" use for its own PARP inhibitor, rucparib, this quarter and expects that a press release about FDA acceptance of the NDA may possibly come in late August. Janney has a Buy rating and $21 fair value estimate on Clovis shares.